Dong L M, Parkin S, Trakhanov S D, Rupp B, Simmons T, Arnold K S, Newhouse Y M, Innerarity T L, Weisgraber K H
Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100, USA.
Nat Struct Biol. 1996 Aug;3(8):718-22. doi: 10.1038/nsb0896-718.
The defective binding of apolipoprotein (apo) E2 to lipoprotein receptors, an underlying cause of type III hyperlipoproteinemia, results from replacement of Arg 158 with Cys, disrupting the naturally occurring salt bridge between Asp 154 and Arg 158. A new bond between Asp 154 and Arg 150 is formed, shifting Arg 150 out of the receptor binding region. Elimination of the 154-150 salt bridge by site-directed mutagenesis of Asp 154 to Ala restored the receptor binding activity to near normal levels. The X-ray crystal structure of apoE2 Ala 154 demonstrated that Arg 150 was relocated within the receptor binding region. Our results demonstrate that defective binding of apoE2 occurs by a novel mechanism of the replacement of one salt bridge with another.
载脂蛋白(apo)E2与脂蛋白受体的结合缺陷是III型高脂蛋白血症的一个潜在原因,它是由半胱氨酸取代精氨酸158所致,破坏了天冬氨酸154和精氨酸158之间天然存在的盐桥。天冬氨酸154和精氨酸150之间形成了一个新的键,使精氨酸150移出受体结合区域。通过将天冬氨酸154定点突变为丙氨酸消除154 - 150盐桥,可使受体结合活性恢复到接近正常水平。apoE2丙氨酸154的X射线晶体结构表明精氨酸150重新定位在受体结合区域内。我们的结果表明,apoE2的结合缺陷是通过一种用另一个盐桥取代一个盐桥的新机制发生的。